Search research articles
Contact Us
Filters
Showing results (291-300 of 302) with videos related to
Page
of 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, et al.
Cancers
|
September 10, 2021
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
Francesco Schettini, Mario Giuliano, Matteo Lambertini, et al.
The Lancet. Oncology
|
November 28, 2021
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Patrick Y Wen, Alexander Stein, Martin van den Bent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Sherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Nature Medicine
|
January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Thomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
Bulletin Du Cancer
|
July 31, 2016
[Breast cancer screening: On our way to the future]
Suzette Delaloge, Thomas Bachelot, François-Clément Bidard, et al.
Plos Medicine
|
December 28, 2016
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
Celine Lefebvre, Thomas Bachelot, Thomas Filleron, et al.
Nature
|
September 7, 2022
Genomics to select treatment for patients with metastatic breast cancer
Fabrice Andre, Thomas Filleron, Maud Kamal, et al.
Nature Communications
|
June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
Davide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
The New England Journal of Medicine
|
October 9, 2016
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
Page
of 31
Search research articles
Search
Showing results (291-300 of 302) with videos related to
Sort By:
Page
of 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, et al.
Cancers
|
September 10, 2021
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
Francesco Schettini, Mario Giuliano, Matteo Lambertini, et al.
The Lancet. Oncology
|
November 28, 2021
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Patrick Y Wen, Alexander Stein, Martin van den Bent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Sherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Nature Medicine
|
January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Thomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
Bulletin Du Cancer
|
July 31, 2016
[Breast cancer screening: On our way to the future]
Suzette Delaloge, Thomas Bachelot, François-Clément Bidard, et al.
Plos Medicine
|
December 28, 2016
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
Celine Lefebvre, Thomas Bachelot, Thomas Filleron, et al.
Nature
|
September 7, 2022
Genomics to select treatment for patients with metastatic breast cancer
Fabrice Andre, Thomas Filleron, Maud Kamal, et al.
Nature Communications
|
June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
Davide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
The New England Journal of Medicine
|
October 9, 2016
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
Page
of 31